Alembic’s Aleor joint venture gets FDA green light for generic desonide

Press enter to search
Close search
Open Menu

Alembic’s Aleor joint venture gets FDA green light for generic desonide

By Sandra Levy - 10/28/2019

Alembic’s joint venture, Aleor Dermaceuticals, has received the Food and Drug Administration’s blessing for desonide ointment, 0.05%.  

The product is the generic of Perrigo’s desonide ointment, 0.05%.

It is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Desonide ointment, 0.05%, had a market value of $13 million for the 12 months ended December 2018, according to IQVIA.

Related Topics